Literature DB >> 15953421

Mu-opioid receptor and CREB activation are required for nicotine reward.

Carrie L Walters1, Jessica N Cleck, Yuo-chen Kuo, Julie A Blendy.   

Abstract

Environmental cues associated with nicotine delivery are an important part of the stimulus that sustains smoking behavior and is often coupled with craving and relapse; however, the neuronal circuitry and molecular substrates underlying this process are still poorly understood. Exposure to an environment previously associated with rewarding properties of nicotine results in an increase of CREB phosphorylation similar to that seen following nicotine administration, and this response is absent in MOR(-/-) mice. Moreover, a single administration of an opioid receptor antagonist, naloxone, blocks both the conditioned molecular response (CREB phosphorylation) and the conditioned behavioral response (nicotine reward) in a place preference paradigm. Lastly, repeated nicotine administration results in increased expression of MORs. However, this effect, along with rewarding properties of nicotine, is blocked in mice with a targeted disruption in the CREB gene. Together, pharmacologic and genetic manipulations indicate that phosphorylation of CREB and upregulation of functional MORs are required for nicotine-conditioned reward.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15953421     DOI: 10.1016/j.neuron.2005.05.005

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  88 in total

1.  Influence of δ-opioid receptors in the behavioral effects of nicotine.

Authors:  Fernando Berrendero; Ainhoa Plaza-Zabala; Lola Galeote; África Flores; S Andreea Bura; Brigitte L Kieffer; Rafael Maldonado
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

Review 2.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

Review 3.  Making a bad thing worse: adverse effects of stress on drug addiction.

Authors:  Jessica N Cleck; Julie A Blendy
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

4.  Central amygdala extracellular signal-regulated kinase signaling pathway is critical to incubation of opiate craving.

Authors:  Yan-Qin Li; Fang-Qiong Li; Xiao-Yi Wang; Ping Wu; Mei Zhao; Chun-Mei Xu; Yavin Shaham; Lin Lu
Journal:  J Neurosci       Date:  2008-12-03       Impact factor: 6.167

Review 5.  [Future medications for tobacco and cannabis dependence].

Authors:  Bernard Le Foll; Zuzana Justinova; Gianlugi Tanda; Steven R Goldberg
Journal:  Bull Acad Natl Med       Date:  2008-01       Impact factor: 0.144

Review 6.  Constitutional mechanisms of vulnerability and resilience to nicotine dependence.

Authors:  N Hiroi; D Scott
Journal:  Mol Psychiatry       Date:  2009-02-24       Impact factor: 15.992

7.  Localized low-level re-expression of high-affinity mesolimbic nicotinic acetylcholine receptors restores nicotine-induced locomotion but not place conditioning.

Authors:  Y S Mineur; D H Brunzell; S R Grady; J M Lindstrom; J M McIntosh; M J Marks; S L King; M R Picciotto
Journal:  Genes Brain Behav       Date:  2008-12-11       Impact factor: 3.449

Review 8.  The delta-opioid receptor and Parkinson's disease.

Authors:  Jin-Zhong Huang; Yi Ren; Yuan Xu; Tao Chen; Terry C Xia; Zhuo-Ri Li; Jian-Nong Zhao; Fei Hua; Shi-Ying Sheng; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2018-08-03       Impact factor: 5.243

9.  Association of smoking with μ-opioid receptor availability before and during naltrexone blockade in alcohol-dependent subjects.

Authors:  Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Xiaoqiang Xu; J James Frost; Dean F Wong; Mary E McCaul
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

Review 10.  Molecular and genetic substrates linking stress and addiction.

Authors:  Lisa A Briand; Julie A Blendy
Journal:  Brain Res       Date:  2009-11-10       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.